Lupin Q1 net profit up 33% at Rs 280 cr

Consolidated net profit rose 33% to Rs 280 crore in the quarter

Drug major today said its consolidated net profit rose by 33.46% to Rs 280.4 crore in the quarter ended June 30, 2012, on the back of robust sales in the US, India and Japan markets.

The company had posted a net profit of Rs 210.1 crore during the same period of previous fiscal.

Net sales of the company for the first quarter ended June 30, rose to Rs 2,219.2 crore as compared to Rs 1,543.2 crore during the same period of previous financial year.

"We had a robust quarter. Strong operating performance aided by product launches and exceptionally strong growth across the US, India, Japan and South Africa have helped us deliver yet another quarter of sustained growth," Managing Director Kamal K Sharma said in a statement.

The Mumbai-headquartered firm's formulation sales in the US and Europe grew by 60% to Rs 841.3 crore during the first quarter ended June 30, as against Rs 524.7 crore during the same period of previous fiscal.

During the quarter, the company's India formulations business grew by 25% to Rs 621.2 crore, as compared to Rs 496.9 crore during the same period of previous fiscal.

"The Indian market contributed 28% of the company's overall revenues for the quarter," the drug firm said.

The company's Japan-based subsidiary Kyowa Pharmaceuticals grew by 100% clocking net sales of Rs 332.9 crore during the quarter, as compared to Rs 166.6 crore during the same period of last fiscal.

Lupin's South African business, Pharma Dynamics posted revenues of Rs 66.3 crore during the quarter, up 13% from the previous fiscal.

The company's active pharmaceutical ingredients (API) sales rose to Rs 231.7 crore during the quarter, as compared to Rs 210.2 crore in the same period of FY 2011-12.

Shares of were trading at Rs 572 on the BSE, up 0.30% from its previous close.

image
Business Standard
177 22
Business Standard

Lupin Q1 net profit up 33% at Rs 280 cr

Consolidated net profit rose 33% to Rs 280 crore in the quarter

Press Trust of India  |  Mumbai 

Drug major today said its consolidated net profit rose by 33.46% to Rs 280.4 crore in the quarter ended June 30, 2012, on the back of robust sales in the US, India and Japan markets.

The company had posted a net profit of Rs 210.1 crore during the same period of previous fiscal.

Net sales of the company for the first quarter ended June 30, rose to Rs 2,219.2 crore as compared to Rs 1,543.2 crore during the same period of previous financial year.

"We had a robust quarter. Strong operating performance aided by product launches and exceptionally strong growth across the US, India, Japan and South Africa have helped us deliver yet another quarter of sustained growth," Managing Director Kamal K Sharma said in a statement.



The Mumbai-headquartered firm's formulation sales in the US and Europe grew by 60% to Rs 841.3 crore during the first quarter ended June 30, as against Rs 524.7 crore during the same period of previous fiscal.

During the quarter, the company's India formulations business grew by 25% to Rs 621.2 crore, as compared to Rs 496.9 crore during the same period of previous fiscal.

"The Indian market contributed 28% of the company's overall revenues for the quarter," the drug firm said.

The company's Japan-based subsidiary Kyowa Pharmaceuticals grew by 100% clocking net sales of Rs 332.9 crore during the quarter, as compared to Rs 166.6 crore during the same period of last fiscal.

Lupin's South African business, Pharma Dynamics posted revenues of Rs 66.3 crore during the quarter, up 13% from the previous fiscal.

The company's active pharmaceutical ingredients (API) sales rose to Rs 231.7 crore during the quarter, as compared to Rs 210.2 crore in the same period of FY 2011-12.

Shares of were trading at Rs 572 on the BSE, up 0.30% from its previous close.

RECOMMENDED FOR YOU

Lupin Q1 net profit up 33% at Rs 280 cr

Consolidated net profit rose 33% to Rs 280 crore in the quarter

Drug major Lupin today said its consolidated net profit rose by 33.46% to Rs 280.4 crore in the quarter ended June 30, 2012, on the back of robust sales in the US, India and Japan markets.

Drug major today said its consolidated net profit rose by 33.46% to Rs 280.4 crore in the quarter ended June 30, 2012, on the back of robust sales in the US, India and Japan markets.

The company had posted a net profit of Rs 210.1 crore during the same period of previous fiscal.

Net sales of the company for the first quarter ended June 30, rose to Rs 2,219.2 crore as compared to Rs 1,543.2 crore during the same period of previous financial year.

"We had a robust quarter. Strong operating performance aided by product launches and exceptionally strong growth across the US, India, Japan and South Africa have helped us deliver yet another quarter of sustained growth," Managing Director Kamal K Sharma said in a statement.

The Mumbai-headquartered firm's formulation sales in the US and Europe grew by 60% to Rs 841.3 crore during the first quarter ended June 30, as against Rs 524.7 crore during the same period of previous fiscal.

During the quarter, the company's India formulations business grew by 25% to Rs 621.2 crore, as compared to Rs 496.9 crore during the same period of previous fiscal.

"The Indian market contributed 28% of the company's overall revenues for the quarter," the drug firm said.

The company's Japan-based subsidiary Kyowa Pharmaceuticals grew by 100% clocking net sales of Rs 332.9 crore during the quarter, as compared to Rs 166.6 crore during the same period of last fiscal.

Lupin's South African business, Pharma Dynamics posted revenues of Rs 66.3 crore during the quarter, up 13% from the previous fiscal.

The company's active pharmaceutical ingredients (API) sales rose to Rs 231.7 crore during the quarter, as compared to Rs 210.2 crore in the same period of FY 2011-12.

Shares of were trading at Rs 572 on the BSE, up 0.30% from its previous close.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard